Clinical trial reveals semaglutide improves blood glucose and weight in schizophrenia with prediabetes, suggesting no negative impact on psychiatric health.
Thirty weeks of treatment with the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide was more effective than placebo in lowering blood glucose and weight in patients with schizophrenia, prediabetes and obesity, a study has found. Treatment with semaglutide did not worsen psychiatric outcomes in these patients relative to placebo. Study results were published online Sept. 3, 2025, in JAMA Psychiatry .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: